A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Nanohale, a German firm developing new formulations of protein and peptide therapeutics, has acquired the R&D and contract development and manufacturing services assets of Scil Technology, bringing them into a new wholly owned subsidiary called Formycon.

Sanofi has exclusively licensed Scil Technology's preclinical stage programme for a regenerative treatment of osteoarthritis and cartilage disorders.

Scil Technology, the German protein drug development and formulation company, has appointed Christian Nafe, currently CFO of the company, to CEO. Mr Nafe succeeds Dr. Weishui Weiser, who retires after 5 years as managing director of Scil Technology.